Home Market Nikkei rises to 3.5-month high on lower yen, marks 8th winning week

Nikkei rises to 3.5-month high on lower yen, marks 8th winning week

8
0
SHARE

TOKYO: Japan's Nikkei share average rose to a 3.5-month high on Friday and scored its eighth straight weekly gain after a weaker yen lifted exporters, while financial stocks extended their rally as US bond yields remained high.

The Nikkei gained 0.4 per cent to 22,930.36, the highest closing level since Feb 2. The benchmark index rose 0.8 per cent on a weekly basis to mark the eighth straight weekly gains, the longest winning streak since a nine-week stretch between September and November.

The dollar rose to its strongest level since Jan. 23 against the yen, hitting 111.00 earlier.

But analysts said that Friday's thin trade and minimal gains suggest the rally may pause.

"Japanese shares have risen on a weaker yen, but I doubt that they keep rising from here just because of the dollar-yen levels," said Shogo Maekawa, global market strategist at JPMorgan Asset Management.

"When you look at global shares, gains in US stocks and emerging market shares have stalled. It is unlikely that Japanese stocks will outperform their global peers."

Trading was thin, with only 1.3 billion shares changing hands on the main board, the lowest level since early April.

The broader Topix gained 0.4 per cent to 1,815.25.

Market players also remain nervous about US-China trade tensions after US President Donald Trump said the world's second largest economy had "become very spoiled on trade".

The weaker yen helped exporters with TDK Corp surging 2.9 per cent, Nissan Motor rising 0.8 per cent and Honda Motor soaring 1.3 per cent.

Financials such as insurers advanced, with T&D Holdings up 2.3 per cent and Dai-ichi Life Holdings adding 1.2 per cent, after US 10-year Treasury yields rose to a near seven-year peak on Thursday, extending this week's bond market selloff.

Elsewhere, PeptiDream jumped 3.0 per cent after the pharmaceutical research company said that it completed the transfer of its proprietary peptide discovery technology to Shionogi & Co Ltd.

Original Article

LEAVE A REPLY

Please enter your comment!
Please enter your name here